2022
Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q
Spurrier J, Nicholson L, Fang XT, Stoner AJ, Toyonaga T, Holden D, Siegert TR, Laird W, Allnutt MA, Chiasseu M, Brody AH, Takahashi H, Nies SH, Pérez-Cañamás A, Sadasivam P, Lee S, Li S, Zhang L, Huang YH, Carson RE, Cai Z, Strittmatter SM. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Science Translational Medicine 2022, 14: eabi8593. PMID: 35648810, PMCID: PMC9554345, DOI: 10.1126/scitranslmed.abi8593.Peer-Reviewed Original ResearchConceptsPositron emission tomographySilent allosteric modulatorsAlzheimer's diseaseMouse modelPhospho-tau accumulationAged mouse modelAlzheimer mouse modelImmune-mediated attackSAM treatmentMicroglial mediatorsSynaptic engulfmentSynaptic lossAD miceComplement component C1qSynapse lossGlutamate responseSynaptic densityDrug washoutSynaptic localizationTherapeutic benefitCognitive impairmentAllosteric modulatorsEmission tomographyNonhuman primatesComponent C1q
2011
Autoimmune Hepatitis: A Review of Current Diagnosis and Treatment
Makol A, Watt KD, Chowdhary VR. Autoimmune Hepatitis: A Review of Current Diagnosis and Treatment. Hepatitis Research And Treatment 2011, 2011: 390916. PMID: 21760995, PMCID: PMC3132488, DOI: 10.1155/2011/390916.Peer-Reviewed Original ResearchAutoimmune hepatitisTreatment end pointsClinical presentationEnd pointChronic indolent diseaseDate diagnostic criteriaEarly liver transplantationNormal liver testsAlternative immunosuppressive agentsImmune-mediated attackLong-term prognosisChronic inflammatory disordersFulminant hepatic failureDiverse clinical manifestationsAggressive initiationAIH patientsCorticosteroid therapyElevated immunoglobulinsLiver testsLiver transplantationHepatic failurePeriportal inflammationImmunosuppressive agentsIndolent diseaseLiver disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply